Obesity and asthma tend to travel together, and when they do, asthma is often harder to control. That overlap has made researchers curious about a practical question: if a person uses a weight-loss medication to address obesity, does that medication itself carry any respiratory risk, or might it actually help?
A systematic review and meta-analysis published in the Annals of the American Thoracic Society tried to answer exactly that. The research team searched four major medical databases plus clinical trial registries, with no restrictions on date or language, and ultimately included 123 studies covering several of the most studied weight-loss compounds. The short answer from the pooled data was broadly reassuring, though with some important gaps.
Scope of the review
The researchers focused on seven approved weight-loss agents: liraglutide, semaglutide, tirzepatide, orlistat, naltrexone-bupropion, phentermine-topiramate, and setmelanotide. Three of those, liraglutide, semaglutide, and tirzepatide, belong to a class that mimics the gut hormone GLP-1 and, in the case of tirzepatide, a second hormone called GIP. These are the peptide-based compounds in the analysis.
The initial search returned 9,086 unique records. After applying eligibility criteria that required randomized controlled trials, non-randomized comparative studies, or large single-group studies, the team narrowed the pool to 123 studies. Of those, 122 evaluated general adult populations, and only one specifically examined people with asthma. The researchers used validated, design-specific tools to assess bias in each study and then ran random-effects meta-analyses to estimate the risk difference between active treatment and placebo.
Main findings on respiratory risk
For liraglutide, semaglutide, tirzepatide, and naltrexone-bupropion, the pooled analysis found no statistically meaningful increase in respiratory adverse events compared with placebo. In plain terms, participants taking these compounds were not more likely to experience breathing problems than participants taking a dummy pill.
For orlistat, phentermine-topiramate, and setmelanotide, the available data were too sparse to draw conclusions. The review authors noted this as a limitation rather than a signal of harm, but it does mean those compounds remain an open question on the respiratory safety front.
The overall risk-of-bias assessment for the randomized trials was favorable. Most studies were judged to carry a low risk of bias, which adds weight to the conclusion that the null finding on respiratory harm reflects real-world safety rather than methodological gaps.
Upper respiratory events and nasopharyngitis
Even though the analysis found no increase in respiratory adverse events relative to placebo, it did document that upper respiratory tract infections and nasopharyngitis, the clinical term for a common cold-like inflammation of the nose and throat, were frequently reported across the included trials.
The incidence of nasopharyngitis ranged widely depending on the compound and treatment duration. For tirzepatide studied over zero to six months, the rate sat at roughly 4.1 percent. For liraglutide studied over thirteen to twenty-four months, it climbed to roughly 23.7 percent. The researchers noted, however, that these rates were not clearly tied to dosing levels or to the specific indication the drug was being used for.
Critically, because placebo arms in the included trials showed similar patterns, the elevated nasopharyngitis numbers likely reflect background rates in the study populations rather than a drug-specific effect. The comparison against placebo is what matters for attributing risk, and that comparison did not favor harm.
The asthma-specific evidence gap
People with asthma represent a population with a particular stake in this question. Obesity worsens asthma control, increases the frequency of exacerbations, and reduces the effectiveness of inhaled treatments. Weight loss itself has been shown in other research to improve asthma outcomes. So knowing whether a weight-loss medication is safe in an asthmatic respiratory system matters clinically.
The review found almost nothing to go on. Only one included study specifically recruited and analyzed individuals with asthma. That single study is not nearly enough to draw population-level conclusions. The authors flagged this as a meaningful evidence gap, calling for future randomized trials that deliberately enroll people with asthma and track respiratory outcomes as a primary or co-primary endpoint.
Interpreting a reassuring but incomplete picture
A systematic review of this scale carries real weight. Pooling data across 123 studies and thousands of participants smooths out the noise that any single trial contains. When that process consistently fails to detect a respiratory signal for the GLP-1-class peptides and naltrexone-bupropion, that absence of signal is meaningful.
At the same time, the literature suggests some caution is warranted in extending the findings. Most of the included studies were designed to measure metabolic or cardiovascular outcomes. Respiratory adverse events were collected as secondary or safety measures, not as primary endpoints. That means the studies may not have had the statistical power or the detailed monitoring protocols to catch subtle respiratory effects. The reassurance is genuine, but it comes from studies that were not purpose-built to detect respiratory harm.
The review also did not address whether these compounds actively improve respiratory function in people who lose weight on them. That question, a positive one rather than a safety one, would require a different study design aimed at measuring lung function, asthma control scores, or exacerbation rates over time.
What this means for research on metabolic peptides
For researchers and informed readers tracking the peptide science space, this meta-analysis fills a useful slot in the safety literature. GLP-1 receptor agonists like liraglutide, semaglutide, and the dual-agonist tirzepatide have accumulated substantial trial data on cardiovascular and metabolic endpoints. Respiratory safety had been a comparatively underexamined corner of that literature. This review consolidates what exists and signals where the gaps remain.
Early data from animal and mechanistic studies have suggested that GLP-1 receptors are present in lung tissue and airways, raising theoretical interest in how these peptides might interact with respiratory physiology. The current meta-analysis does not resolve that mechanistic question, but it does indicate that at the clinical trial level, no harmful respiratory pattern has emerged in general adult populations.
The call for dedicated asthma trials is the most actionable takeaway for the research community. Until those trials exist, the intersection of weight-loss peptides and asthmatic airways remains a space where the literature suggests safety is plausible but evidence is thin.
